Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

The current treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) has been greatly impacted in the past decade by the introduction of antibody–drug conjugates (ADCs), which represent a relatively novel therapeutic class with the peculiar abi...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonarelli, G., Corti, C., Tarantino, P., Salimbeni, B.T., Zagami, P., Marra, A., Trapani, D., Tolaney, S., Cortes, J., Curigliano, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372550/
https://www.ncbi.nlm.nih.gov/pubmed/37467660
http://dx.doi.org/10.1016/j.esmoop.2023.101608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372550/
https://www.ncbi.nlm.nih.gov/pubmed/37467660
http://dx.doi.org/10.1016/j.esmoop.2023.101608

Ejemplares similares